Lantern Pharma Inc.

Lantern Pharma Inc. is a clinical-stage biopharmaceutical company focused on oncology, leveraging artificial intelligence (AI), machine learning, and genomic data to accelerate and transform the drug discovery and development process for cancer therapies. The company's mission is to identify and develop novel cancer treatments more efficiently and cost-effectively. Its headquarters are located in Dallas, Texas, United States.

Lantern Pharma utilizes its proprietary AI platform, RADR®, which encompasses over 200 billion data points, to identify biologically relevant genomic signatures correlated with drug response. This platform helps to pinpoint cancer patients who are most likely to benefit from their compounds. The company's pipeline includes three lead small molecule drug candidates—LP-300, LP-184, and LP-284—which target solid tumors and blood cancers. Additionally, they have an antibody-drug conjugate (ADC) program spanning 12 cancer indications and advance programs through a subsidiary focused on central nervous system and brain cancers. They recently launched withZeta.ai, an AI co-scientist platform designed for rare cancer drug discovery and development.

Lantern Pharma became a publicly traded company in June 2020. Recent notable developments include the upcoming public demonstration of their withZeta.ai platform in April 2026, following its scientific debut. The company has also scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for amendments to its HARMONIC trial and reported positive Phase 1a data for LP-184 in advanced solid tumors. Panna L. Sharma serves as the Chief Executive Officer, President, and Director, leading the company's efforts to position itself as an AI-driven precision oncology firm aiming to reduce the time and cost associated with traditional cancer drug development.